Vaginal Estradiol and Metformin Interaction: What Patients and Clinicians Need to Know

Is there an interaction between vaginal estradiol and metformin?

Not one that runs through drug levels. The metformin hydrochloride tablets label describes no interaction that would change estradiol exposure, and the estradiol labels describe no interaction that would change metformin exposure [1][3][2]. Metformin is not metabolized and leaves the body unchanged in urine, while estradiol is partly metabolized by CYP3A4 [1][3][2].

The estradiol labels say estrogens are metabolized partly by CYP3A4, so inducers such as St. John's wort, phenobarbital, carbamazepine and rifampin may lower estrogen levels, and inhibitors such as erythromycin, clarithromycin, ketoconazole, itraconazole, ritonavir and grapefruit juice may raise them [3][2]. Metformin is not on either list.

Where the two labels do cross: blood glucose

The metformin label has a row headed Drugs Affecting Glycemic Control. It states that certain drugs tend to produce hyperglycemia and may lead to loss of glycemic control, and names estrogens and oral contraceptives among the examples, together with thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, phenytoin, nicotinic acid, sympathomimetics, calcium channel blockers and isoniazid [1]. The label says to observe the patient closely for loss of blood glucose control when such a drug is given, and to observe closely for hypoglycemia when it is withdrawn [1].

The list does not separate oral estrogens from vaginal estrogens [1].

What the vaginal estradiol label says

The estradiol vaginal label covers Estradiol Vaginal Cream, 0.01%, which is indicated for moderate to severe symptoms of vulvar and vaginal atrophy due to menopause [2]. Two passages matter for this question.

In its warnings, the label states: 'Systemic absorption may occur with the use of Estradiol Vaginal Cream, 0.01%. The warnings, precautions, and adverse reactions associated with oral estrogen treatment should be taken into account' [2].

In its drug-laboratory test interactions, the fifth item is impaired glucose tolerance [2]. Its list of adverse reactions reported with estrogen and/or progestin therapy includes glucose intolerance [2].

The oral estradiol tablet label similarly lists reduced carbohydrate tolerance among the adverse reactions reported with estrogen therapy [3].

Where clearance sits in the metformin label

Metformin's label puts the clearance question in a different row. Drugs that interfere with the renal organic cation transporter 2 (OCT2) and multidrug and toxin extrusion (MATE) transporters — ranolazine, vandetanib, dolutegravir and cimetidine — can raise metformin exposure, and carbonic anhydrase inhibitors such as topiramate can increase the risk of lactic acidosis [1]. Estrogens appear in the glycemic-control row, not in either of those rows [1].

Metformin also carries a boxed warning for lactic acidosis, with risk factors that include renal impairment, age 65 or older, radiologic studies with contrast, surgery and other procedures, hypoxic states such as acute congestive heart failure, excessive alcohol intake, hepatic impairment and mitochondrial disease [1]. Vaginal estradiol is not among those named risk factors.

If estrogen is started or stopped

The metformin label's instruction covers the whole class of drugs that affect glycemic control, so it applies when an estrogen product is given and again when one is withdrawn [1]. The label asks for close observation for loss of glucose control in the first case and for hypoglycemia in the second [1].

Metformin monitoring that does not change

Metformin's label calls for kidney-function checks before treatment and at least annually, plus vitamin B12 checks every 2 to 3 years [1]. It sets eGFR limits — contraindicated below 30 mL/min/1.73 m2, with starting not recommended at 30 to 45 [1]. In 29-week trials, subnormal vitamin B12 levels occurred in about 7% of patients [1]. Those instructions are not specific to vaginal estradiol.

What the labels do not say

The metformin label gives no figure for how much blood glucose changes when an estrogen is given, and the vaginal cream label gives none either [1][2]. The size of any glucose change with vaginal estradiol is therefore not stated.